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treatment option as compared with escitalopram,sertraline, and venlafaxine in 
a matrix comparator, with regard to side effects especially sexual dysfunction, 
agomelatine should be considered as the most cost-effective option for treat-
ment of depression.
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Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia and can reduce inpatient 
stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting 
injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment 
of schizophrenia in Germany. The study aims at estimating, based on a previously 
published model, the cost-effectiveness of paliperidone long-acting injections com-
pared to other common antipsychotic treatment strategies in patients diagnosed 
with schizophrenia in Germany. MethOds: A Markov decision analytic model was 
adapted to the German health care system. The model considers the cost-effective-
ness for PLAI as a maintenance treatment for patients with schizophrenia from the 
payer perspective. The patients transition between eight health states on a monthly 
basis over a 5-year time horizon. As therapeutic strategies PLAI, quetiapine, risperi-
done long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol 
decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical 
were compared. Probability of relapse, level of adherence, side effects and treatment 
discontinuation were derived from the Swedish original model. Input factors regard-
ing resource use and costs were estimated and adjusted for the German health care 
system. A probabilistic sensitivity analyses using cost-effectiveness scatter plots 
was performed to visualize the robustness of the results. Results: In base case 
scenario PLAI is superior to RLAI in gained quality adjusted life years (QALYs) and 
avoided relapses. Relative to all other treatment strategies PLAI is more effective 
with regard to gained QALYs and avoided relapses but results in higher treatment 
costs over a 5-year horizon in base case scenario. The results were tested in proba-
bilistic sensitivity analyses cOnclusiOns: PLAI dominates RLAI and compared to 
the other treatment strategies PLAI has shown to be more effective but results in 
higher costs in base case scenario.
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Depression is present in 10% of patients attending primary care services and is 
generally not identified. In Mexico it is estimated a prevalence of 12% to 20% among 
adults between 18-65 years old. Up to 75% of patients treated with a selective inhibi-
tor of serotonin reuptake (SSRIs) are not responding adequately. Atypical antipsy-
chotics are an effective alternative for these patients. Objectives: To evaluate the 
cost-effectiveness (CE) of extended release (XR) quetiapine as adjunctive therapy 
(AT) in patients with major depressive disorder (MDD) that doesn’t respond to 
antidepressant treatment (AD), compared with other antipsychotics listed in the 
Mexican Formulary (aripiprazole and olanzapine). MethOds: A Markov model 
was developed to perform and incremental analysis with weekly cycles during 
eight weeks time horizon, based on the meta-analysis developed by Komossa et.al 
in 2010. Health states: remission, relapse and discontinuation of treatment. The 
model estimates the remission time gained (RG) by each AT alternative. The analy-
sis was done from society perspective, considered direct costs, and reported in 
2013 US dollars. Results: Patients with AT with quetiapine XR had 1.83 weeks 
of RG, while patients under aripiprazole and olanzapine obtained 1.5 and 1.72 
weeks of RG, respectively. Quetiapine XR compared to olanzapine generated an 
additional cost per patient of $94.70, with additional RG of 0.11 weeks and ICER 
of $881.73. Quetiapine XR dominated extendedly to aripiprazole. Robustness of 
results were confirmed by additional deterministic and probabilistic sensitivity 
analysis. cOnclusiOns: The use of quetiapine XR as adjuvant treatment for non-
responders patients is a cost-effective compared to aripiprazole and olanzapine, 
and could be considered as an option in an institutional setting.
PMH36
How sHoUld an antidEPrEssant witH rEdUCEd risk of sExUal 
dysfUnCtion BE PositionEd in trEatMEnt stratEGiEs for PatiEnts 
witH Major dEPrEssivE disordEr?
Massetti M.1, Vataire A.L.2, Cristeau O.2, Toumi M.3, Aballea S.4
1University Paris-Est Creteil Val de Marne, Paris, France, 2Creativ-Ceutical, PARIS, France, 
3University Claude Bernard Lyon 1, Lyon, France, 4Creativ-Ceutical, Paris, France
Objectives: Sexual dysfunctions (SD) is a common adverse event of antidepressants. 
It has a lasting impact on quality of life and is associated with an increased risk of 
early treatment discontinuation. Using an open-source Discrete Event Simulation 
model (https://open-model-mdd.org/), we performed a cost-effectiveness analysis 
comparing alternative sequences of treatments, to determine whether an antidepres-
sant with moderate efficacy and reduced risk of SD should be positioned before or 
after a treatment with high efficacy and average risk of SD. MethOds: The model 
used was designed to simulate costs and QALYs in cohorts of patients with major 
depressive disorder (MDD), under alternative treatment strategies over 5 years. 
Each strategy consisted of up to 4 lines of treatment, with possibility to switch to 
different drugs when a patient experienced adverse events or lack of efficacy. We 
between 2006 and 2012. Results: Our findings indicate that in the assessed time 
period an average yearly amount of approximately € 5,5 million (calculation based 
on yearly average EUR/HUF exchange rates) is spent on second generation antip-
sychotics, which are prescribed and purchased with reimbursement but finally 
not used by the patients due to early medication discontinuation. Based on our 
calculations, the average yearly treatment costs of antipsychotics increased from 
€ 612 (2006) to € 974 (2012) per patient in the assessed time period. The analysis of 
the NHIF database resulted, that the average yearly expenditure on different antip-
sychotics, varied between € 173 and € 2420 per patient. cOnclusiOns: All-cause 
medication discontinuation is a major concern in the treatment of schizophrenia 
both from a clinical and both from a health economic perspective. In order to 
ensure resources are spent cost-effectively, it is crucial to identify methods which 
can improve treatment continuation and adherence of schizophrenia patients 
in the future.
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Objectives: To compare the effect of adjunctive therapy with pregabalin versus 
usual care (UC) on health care costs and clinical and patients consequences in 
Generalized Anxiety Disorder (GAD) subjects with partial response (PR) to previous 
SSRI course in medical practice in Spain. MethOds: Post-hoc analysis of patients 
with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. 
PR was defined as a Clinical-Global-Impression scale score > 3 and insufficient 
response with persistence of anxiety symptoms > 16 in the Hamilton-Anxiety scale. 
Two groups (based on psychiatrist judgment) were analyzed 1) adjunctive therapy 
(AT) with pregabalin (150-600 mg/day) to existing therapy; or 2) usual care (switching 
to a different SSRI or adding another anxiolytic different than pregabalin). Costs 
estimation used year-2009 prices for GAD related health care resources utilization. 
Consequences were a health profile based on the combination of psychiatrist-based-
measurements [HAM-A, CGI and Montgomery-Asberg-Depression-Rating (MADRS) 
scales], and patient-reported-outcomes [sleep (MOS-sleep), disability (WHO-DAAS 
II) and quality-of-life/quality-adjusted-life-year gain (EQ-5D)]. Changes in both 
health care costs and scale scores were compared separately at end-of-trial visit 
by a general-linear-model with covariates. Results: Four-hundred-eighty-six 
newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) 
and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with signifi-
cantly higher mean (95% CI) score reductions vs. UC in HAM-A [-14.9(-15.6;-14.2) vs. 
-11.2(-12.2;-10.2), p< 0.001] and MADRS [-11.6(-12.2;-10.9) vs. -7.8(-8.7;-6.8), p< 0.001]. 
Changes in all patient-reported-outcomes favored significantly patients receiving 
pregabalin, including QALY gain; 0.13(0.12;0.14) vs. 0.09(0.07;0.10), p< 0.001. Health 
care costs were significantly reduced in both cohorts yielding similar 6-month costs; 
€ 1543 (1375;1711) UC and € 1497 (1380;1614) pregabalin, p= 0.661. The effect of sex on 
costs and consequences were negligible. cOnclusiOns: In medical practice, GAD 
patients with PR to SSRI experienced greater consequences improvements with 
adjunctive therapy with pregabalin versus UC, without increasing health care cost. 
The effect of pregabalin was independent of patient gender.
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Objectives: To compare cost-effectiveness of agomelatine versus an escitalo-
pram-sertraline-venlafaxine matrix comparator. MethOds: A DESM describes 
course of depressive disorders with acute , continuation, and maintenance treat-
ment of depression in Thai setting for 24 months. A sample of 250,000 patients 
with 100 simulations were assumed with Exigo® model. Antidepressants were 
analyzed for treatment of episodes(12-24 weeks),continuation phase(6-9 months), 
maintenance phase over 2 years follow-up. Data inputs included Thai data on 
disease parameters; Cost included antidepressants, drugs for insomnia, sexual 
side-effects, cognitive behavioral therapy(CBT), electroconvulsive therapy(ECT) 
and mean cost of psychiatric visits. Impact measures were derived from a sys-
temic review. Results were presented as cost(Thai-Baht currency-THB) per Life-
Year-Remission(LYR) averted and Quality-Adjusted Life Year(QALY) compared with 
branded antidepressants in the matrix comparator (46%escitalopram, 33%ser-
traline, 21%venlafaxine). Model simulation initiated with either agomelatine 
25mg or comparators(escitalopram10mg,sertraline100mg,venlafaxine 150mg 
by random selection). Relapse cases required dose increase fro each antidepres-
sant, addition of CBT and ECT. Data on impact of treatment on quality of life in 
patients free from relapse, sexual side effects, insomnia were taken from cochrane 
database. Results: During 24 months, patients treated with agomelatine cost 
15,814.2THB and 20,232.0THB per LYR and QALY gains, whereas with compara-
tor cost 17,999.6THB and 23,431.7THB per LYR and QALY gains. As a result, the 
incremental cost-effectiveness ratio(ICER) shows that agomelatine is the most 
cost-effective antidepressant for episodic treatment with/without continua-
tion or maintenance phase, its cost being lower than comparator by 153,283 and 
83,645 THB per LYR and QALY. These results were robust, probability sensitiv-
ity analysis suggested that agomelatine was effective for a willingness-to-pay 
of 300,000THB,95%CI of -146,120.4 to -179,651.0THB per QALY, with probability of 
> 0.90. cOnclusiOns: Based on the model, agomelatine is the most cost-effective 
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tions (CVC). A number of models are available for the evaluation of the economic 
impact of antipsychotics in schizophrenia, but few of them properly consider 
metabolic syndrome and associated complications. The objective of this study 
was to build a new model to reflect the real patient therapeutic management of 
patients with schizophrenia. MethOds: An expert meeting was set up to vali-
date the design of the model, and to list all outcomes that should be included 
in the model structure. The model was programmed in Excel 2010, with VBA 
coding. Results: The expert meeting validated the premise that the aim of the 
treatment is to prevent relapses, affecting patients’ quality of life and generating 
substantial costs. A patient-level Markov model structure was used, to simulate 
a cohort of patients with schizophrenia over lifetime, with 6-month cycles. Five 
lines of treatments are considered in the model. With up to 3 comparators in 
the first cycle, it models patients’ treatment adjustment, and provides the flex-
ibility to specify at any line of treatment a specific distribution of antipsychotics. 
The model considers treatment response, associated side effects (weight gain, 
sexual dysfunction, EPS and sedation), diabetes diagnosis and CVC (coronary 
heart disease and stroke). Non-response and compliance (based on side effects) 
drive relapse and hospitalization. Each relapse is assumed to require a treatment 
switch. Patients are also allowed to escape from the health care system, or to die, 
due to natural death, suicide or CVC-related death. Finally, extensive determinis-
tic and probabilistic sensitivity analyses are also implemented. cOnclusiOns: 
This new economic model allows taking into account all key features of schizo-
phrenia, in a transparent way.
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Objectives: Asenapine is a new atypical antipsychotic approved in Turkey for the 
treatment of schizophrenia and bipolar I disorder. Asenapine has demonstrated 
comparable efficacy over olanzapine in controlling both positive and negative symp-
toms of schizophrenia in the long-term. However, unlike olanzapine, asenapine is 
associated with a favorable metabolic profile as well as with a minimal weight gain. 
Post-hoc analyses of a clinical study vs. olanzapine illustrated higher incidence of 
developing metabolic syndrome (MetS) with olanzapine than with asenapine after 
52 weeks of treatment. The aim of this study is to assess the cost-effectiveness of 
asenapine in schizophrenia compared with the most widely used atypical antip-
sychotics in Turkey with a focus on the long-term consequences of MetS which 
increases the risk of diabetes and cardiovascular diseases (CVD). MethOds: 
Perspective of National Pharmaceutical Reimbursement Authority was applied and 
life expectancy horizon was adopted. Annual risks of metabolic syndrome were 
derived from randomized clinical studies of asenapine and indirect comparison of 
other atypical antipsychotics vs. olanzapine. Risks of developing diabetes and CVD 
were based on published risk models. Treatment costs associated with metabolic 
consequences as well as cost of atypical antipsychotics were derived from local 
sources. Number of diabetes and CVD avoided is used as effectiveness measure in 
the model. Results: Asenapine dominates (more effective and less expensive) all 
atypical antipsychotics in the treatment of schizophrenia. Compared to olanzapine, 
quetiapine, aripiprazole, risperidone and paliperidone (all genericized except pali-
peridone), asenapine was associated with incremental total costs of 1908 TL, 1298 TL, 
314 TL, 841 TL and 1958 TL; and associated with incremental total number of diabetes 
& CVD avoided of 0.046, 0.029, 0.001, 0.028 and 0.028 respectively. cOnclusiOns: 
The lower incidence of developing MetS associated with asenapine compared to 
olanzapine and other atypicals is associated with lower treatment costs and lower 
incidence of diabetes and CVD in Turkey.
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Objectives: Asenapine is a new atypical antipsychotic approved in Turkey for the 
treatment of bipolar I disorder (BD-I) and schizophrenia. Asenapine has demon-
strated comparable antimanic efficacy over olanzapine in a head-to-head study. 
However, unlike olanzapine, asenapine is associated with a favorable metabolic 
profile as well as with a minimal weight gain. Post-hoc analyses of a clinical study 
vs. olanzapine illustrated higher incidence of developing metabolic syndrome 
(MetS) with olanzapine than with asenapine after 52 weeks of treatment. The 
aim of this study is to assess the cost-effectiveness of asenapine in the treat-
ment of BD-I compared with the most widely used atypical antipsychotics with 
a focus on the long-term consequences of MetS which increases the risk of dia-
betes and cardiovascular diseases (CVD). MethOds: Perspective of National 
Pharmaceutical Reimbursement Authority was applied and life expectancy hori-
zon was adopted. Risks of metabolic syndrome after 52 weeks of treatment were 
derived from randomized clinical studies of asenapine and indirect comparison of 
other atypical antipsychotics vs olanzapine. Risks of developing diabetes and CVD 
were based on published risk models. Treatment costs associated with metabolic 
consequences as well as cost of atypical antipsychotics were derived from local 
sources. Number of diabetes and CVD avoided is used as effectiveness measure 
in the model. Results: Asenapine dominates (more effective and less expensive) 
all atypical antipsychotics in the treatment of BD-I. Compared to olanzapine, 
quetiapine, aripiprazole, risperidone and paliperidone (all genericized), asenapine 
was associated with incremental total costs of 2418 TL, 1786 TL, 804 TL and 877 
TL; and associated with incremental total number of diabetes & CVD avoided of 
0.054, 0.038, 0.010 and 0.037 respectively. cOnclusiOns: The lower incidence of 
developing MetS associated with asenapine compared to olanzapine and other 
atypicals is associated with lower treatment costs and lower incidence of diabetes 
and CVD in Turkey.
compared two strategies based on hypothetical treatments: under strategy A, an 
antidepressant with high response rate/high SD rate was prescribed in first-line and 
an antidepressant with moderate response rate/low SD rate available in second-line; 
under strategy B, the positions of these two drugs were reversed. Efficacy and safety 
parameters were obtained from a meta-analysis and other parameters, from the 
literature. Costs were estimated for the UK, from payer perspective. Results: The 
numbers of QALYs were estimated at 3.660 QALYs (SE= 0.013) and 3.649 (SE= 0.012) 
under strategies A and B respectively. Costs were estimated at £3,894 (SE= 60) and 
£3,918 (SE= 61). cOnclusiOns: Positioning an antidepressant with moderate efficacy 
and reduced risk of SD before or after a treatment with high efficacy and average risk 
of SD had no significant impact in terms of average costs and QALYs. Thus, differences 
in efficacy and tolerability can offset each other. In practice, the choice of first-line 
treatment should take account of patient preferences.
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Objectives: To determine the cost-effectiveness of paliperidone palmitate (PP-LAI; 
paliperidone long-acting injectable), a new once-monthly long-acting antipsychotic 
therapy, compared with risperidone long-acting injectable (RLAI) administered 
biweekly for treating chronic schizophrenia in Poland from the National Health 
Fund (NHF) perspective. MethOds: We adapted a 1-year decision tree model to 
the Polish health care system with literature-derived data (e.g., length of stay in 
hospital, treatment patterns, resource utilization) and clinical expert inputs. Costs 
in 2012 euros were obtained from published sources or in case of non-reimbursed 
drug price, directly from producer. Drugs compared were PP-LAI, a new treatment 
option, and RLAI, the established treatment for Polish patients. Clinical rates were 
derived from published trials. Model outputs included expected cost/patient as 
well as rates of hospitalization, emergency room visits, days free of symptoms, and 
quality-adjusted life-years (QALYs). One-way sensitivity analyses were applied to 
major inputs. As well, all inputs were varied simultaneously in probabilistic sensitiv-
ity analyses using 10,000 iterations. Results: Despite its higher acquisition cost, 
PP-LAI had a lower expected cost per patient treated when the benefits are included 
in the estimation model. PP-LAI was associated with 0.824 QALYS, 323 days with 
stable disease and 44.6% hospitalization. RIS-LAI had 0.817 QALY, 317 stable days and 
51.3% hospitalizations. PP-LAI dominated RIS-LAI in the base case and in 55.0% of 
10,000 simulations, and was cost-effective in 76.6%. However, cost-effectiveness was 
sensitive; it was lost with modest increases for PP-LAI or decreases for comparison 
drugs with respect to drug prices, relapse rates and adherence rates. Because it is 
injected monthly as opposed to biweekly, it saves caregiver time. cOnclusiOns: 
From the viewpoint of the National Health Fund of Poland, as compared with RLAI, 
PP-LAI is a cost-effective drug that has the potential to reduce health care costs.
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Objectives: To evaluate the cost-effectiveness of using a combination of atypical 
antipsychotic agents and mood stabilizers in maintenance treatment of bipolar dis-
order in Brazil MethOds: Analyzing cost-effectiveness, taking direct costs, from the 
perspective of Brazil’s Ministry of Health and its public health system (local acro-
nym SUS), using a Markov model with transitions between possible states: euthy-
mia, mania, depression, discontinuation and death. Efficacy data to populate the 
model were extracted from clinical trials and prospective cohort studies while direct 
cost data came from the public health system’s databases (current values of 2012, 
exchange rate: US$ 1 = R$ 2.21). For a hypothetical cohort of 2000 euthymic individu-
als aged 40, maintenance therapy costs and outcomes were simulated over quarterly 
cycles through a timeframe that reached an effectiveness of < 1 day in remission, for 
up to 30 years. Discount rates and half-cycle correction were applied, also, sensitiv-
ity analyses were run. Results: The available efficacy data enabled the analysis to 
include only a combination with quetiapine. After twelve years (48 cycles) tracking the 
hypothetical cohort, there were 512 acute episodes (285 depression and 227 mania) for 
monotherapy against 306 (166 depression and 139 mania) for the quetiapine combina-
tion. The incremental cost-effectiveness ratio (ICER) for the quetiapine combination 
therapy was US$ 565.64 per additional month in remission. The sensitivity analysis 
with all variables demonstrated the model’s robustness, while dosage and quetiapine-
price variations had most impact, showing an ICER ranging from US$ 381.88 to US$ 
811.24 per additional month in remission. cOnclusiOns: Maintaining the euthymia 
in bipolar disorder has a clinical relevance, especially, because of its impact on func-
tional capacity in this population. In this context, in specific populations, the ICER 
shown may justify the use of the therapeutic strategy presented here. This reimburse-
ment by public systems should also consider its budget impact.
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Objectives: Antipsychotic treatments can cause several side effects, such as 
weight gain, metabolic syndrome, which could lead to cardiovascular complica-
